BTK and diffuse large B-cell lymphoma: The result of Temsirolimus was that it was less active and more toxic than the Bruton Tyrosine Kinase (BTK) inhibitor ibrutinib [9] and the addition of everolimus after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) did not improve the outcome of patients with newly diagnosed high-risk diffuse large B cell lymphoma (DLBCL) [10].